The FaibaGo Study - Long-Term Weight Reduction Via Low-Threshold Intervention

Exclusion Criteria19

• Systemic antibiotic use within the last 2 months
• History of bariatric surgery
• Initiation or dose adjustment of pharmaceutical treatment for dyslipidemia or hyperglycemia within the last 3 months or during the study (e.g., metformin, statins, SGLT2 inhibitors)
• Use of prebiotic or probiotic supplementation (duration >1 month) within the last 6 weeks (at PI's discretion, based on medication summary of TP)
• Medical weight management treatments within the last year (e.g., Glucagon-Like Peptide-1 (GLP-1) agonists)
• Recent (<1 month) dose adjustment, initiation or termination of proton pump inhibitors use (e.g., pantoprazole, omeprazole)
• Professionally supervised intensive (>6 months of ongoing supervision) weight management treatments (e.g., structured nutrition counselling) within the last year (at the PI's discretion)
• Diagnosis of Type 1 or Type 2 diabetes requiring bolus insulin therapy or frequent dose adjustments in base line insulin
• Regular alcohol consumption exceeding two (women) or three (men) standard units (10 g of pure alcohol) per day
• Consumption of more than one nicotine product (e.g., (e-)cigarette, gum) per month
• Regular drug abuse (once per week over the past 4 months)
• Any stage of known pregnancy or lactation period (self-reported)
• Active cancer or recent cancer treatment (within the last 4 months)
• Chronic, active inflammatory diseases (e.g., inflammatory bowel disease, rheumatoid arthritis)
• Severe gastrointestinal disorders (e.g., celiac disease, short bowel syndrome, gastroparesis)
• Known eating disorder (medically diagnosed)
• Participation in another investigation with an investigational drug within the 30 days preceding randomisation
• Dependency from the Sponsor-Investigator
• Last visit with TP > 22 days prior to eligibility assessment